Edition:
India

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Capital Market

1.62USD
9:17pm IST
Change (% chg)

$-0.07 (-4.14%)
Prev Close
$1.69
Open
$1.65
Day's High
$1.75
Day's Low
$1.62
Volume
21,108
Avg. Vol
430,819
52-wk High
$8.37
52-wk Low
$0.65

Latest Key Developments (Source: Significant Developments)

VTV Therapeutics Says Initiated Corporate Restructuring To Continue Development Of Drug Candidates Using External Resources
Wednesday, 12 Dec 2018 

Dec 11 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS - ON DEC 11, 2018, INITIATED A CORPORATE RESTRUCTURING TO CONTINUE DEVELOPMENT OF DRUG CANDIDATES USING EXTERNAL RESOURCES.VTV THERAPEUTICS - RESTRUCTURING INCLUDES REDUCTION IN WORKFORCE AFFECTING ABOUT 65% OF EMPLOYEES, AS OF DEC 11, 2018.VTV THERAPEUTICS- EXPECTS TO COMPLETE REDUCTIONS IN HEADCOUNT, INCLUDING PAYMENT OF EMPLOYEE SEVERANCE & BENEFITS, IN Q2 OF 2019.VTV THERAPEUTICS - EXPECTS RESTRUCTURING ACTIONS TO RESULT IN ANNUALIZED COST SAVINGS OF ABOUT $3.7 MILLION.VTV THERAPEUTICS - EXPECTS RESTRUCTURING ACTIONS TO RESULT IN RESTRUCTURING CHARGE OF ABOUT $0.8 MILLION FOR EMPLOYEE SEVERANCE & RELATED COSTS.  Full Article

Vtv Therapeutics Announces Transfer Of Listing To The Nasdaq Capital Market
Tuesday, 30 Oct 2018 

vTv Therapeutics Inc ::VTV THERAPEUTICS ANNOUNCES TRANSFER OF LISTING TO THE NASDAQ CAPITAL MARKET.VTV THERAPEUTICS INC - SECURITIES WILL BE TRANSFERRED FROM NASDAQ GLOBAL MARKET TO NASDAQ CAPITAL MARKET AT OPENING OF BUSINESS ON OCTOBER 30.  Full Article

vTv Therapeutics Inc Received Written Response From FDA For Azeliragon
Saturday, 22 Sep 2018 

Sept 21 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS INC - ON SEPT 17, CO RECEIVED WRITTEN RESPONSE FROM FDA TO ITS TYPE C MEETING REQUEST SEEKING DEVELOPMENT GUIDANCE FOR AZELIRAGON.VTV THERAPEUTICS INC - FDA ADVISED THAT EFFICACY OF AZELIRAGON SHOULD BE DEMONSTRATED IN AT LEAST TWO ADEQUATE & WELL-CONTROLLED TRIALS- SEC FILING.  Full Article

vTv Therapeutics Qtrly GAAP Net Loss Per Share Was $0.31
Friday, 3 Aug 2018 

Aug 3 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 RESULTS AND UPDATE.VTV THERAPEUTICS INC - QTRLY GAAP NET LOSS PER SHARE WAS $0.31.VTV THERAPEUTICS INC - QTRLY REVENUE $2.5 MILLION VERSUS $13,000.  Full Article

vTv Therapeutics Announces Licensing Agreement With Newsoara Biopharma Co
Thursday, 31 May 2018 

May 31 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS ANNOUNCES LICENSING AGREEMENT WITH NEWSOARA BIOPHARMA CO. LTD. TO RIGHTS FOR VTV’S PDE4 INHIBITOR IN CHINA AND OTHER PACIFIC RIM TERRITORIES.VTV THERAPEUTICS INC - CO WILL RECEIVE AN UPFRONT PAYMENT.VTV THERAPEUTICS - CO WILL BE ELIGIBLE TO RECEIVE FUTURE DEVELOPMENT & COMMERCIALIZATION MILESTONES AS WELL AS ROYALTIES ON SALES OF APPROVED PRODUCTS.VTV THERAPEUTICS INC - NEWSOARA WILL DEVELOP HPP737 IN COVERED TERRITORIES FOR RESPIRATORY AND OTHER INFLAMMATORY DISEASES.  Full Article

vTv Therapeutics Q1 GAAP Loss Per Share $0.30
Wednesday, 16 May 2018 

May 15 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS.Q1 GAAP LOSS PER SHARE $0.30.Q1 EARNINGS PER SHARE VIEW $-0.34 -- THOMSON REUTERS I/B/E/S.  Full Article

Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement
Friday, 22 Dec 2017 

Dec 21 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL RECEIVE AN UPFRONT PAYMENT.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL ALSO RECEIVE SHARES OF RENEO PHARMACEUTICALS' COMMON STOCK.  Full Article

vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM.VTV THERAPEUTICS-GRANTED HUADONG PHARMACEUTICAL EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE GLP-1R AGONIST PROGRAM IN CHINA, HK, AND OTHER COUNTRIES.VTV THERAPEUTICS INC SAYS WILL RECEIVE AN $8 MILLION UPFRONT PAYMENT AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $75 MILLION IN MILESTONE PAYMENTS.  Full Article

VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING.VTV THERAPEUTICS INC - ENTERED AGREEMENT FOR INVESTOR'S COMMITMENT TO PURCHASE, CO'S CLASS A COMMON STOCK AT $4.38/SHARE.VTV THERAPEUTICS INC - AMOUNT OF COMMON STOCK THAT MAY BE PURCHASED BY INVESTOR PURSUANT TO LETTER AGREEMENT IS LIMITED TO $10.0 MILLION.  Full Article

vTv Therapeutics reports Q3 GAAP loss per share of $0.38
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Vtv Therapeutics Inc ::vTv Therapeutics reports third quarter 2017 financial and operational results.Q3 GAAP loss per share $0.38.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Qtrly ‍non-GAAP net loss per fully exchanged share was $0.38​.Research and development expenses were $9.0 million in Q3 of 2017, compared to $9.6 million in Q2 of 2017​.  Full Article